Analyst firms · Morgan Stanley · BIIB

Morgan Stanley BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

Morgan Stanley rates Biogen Inc. (BIIB) Equal-Weight with a $204 price target, as of its latest action on Oct 31, 2024. It has published 8 rating actions on BIIB since July 2021, including 0 upgrades and 1 downgrade. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

Current rating
Equal-Weight
Price target
$204
Median target, all firms
$231.50
Actions on BIIB
8

Morgan Stanley price target on BIIB

$455$330$20420222023202420252026
Morgan Stanley price target on BIIB, each point a stated target, July 2021 to October 2024.

Every Morgan Stanley rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about Morgan Stanley and BIIB

What is Morgan Stanley's price target for BIIB?
Morgan Stanley's latest stated price target for Biogen Inc. (BIIB) is $204, from its action on Oct 31, 2024.
What is Morgan Stanley's rating on BIIB?
Morgan Stanley rates BIIB Equal-Weight, a neutral rating, as of Oct 31, 2024.
When did Morgan Stanley last change its view on BIIB?
On Oct 31, 2024, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $285 to $204.
How does Morgan Stanley's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

More BIIB rating histories

All Morgan Stanley ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.